During the past decade, CHU de Besançon conducted 687 clinical trials. In the 10-year time frame, 687 clinical trials started and 85 clinical trials were completed, i.e. on average, 12.4% percent of trials that started reached the finish line to date. In the past 5 years, 293 clinical trials started and 66 clinical trials were completed. i.e. 22.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU de Besançon" #1 sponsor was "Centre Hospitalier Universitaire de Besancon" with 224 trials, followed by "UNICANCER" with 27 trials sponsored, "European Organisation for Research and Treatment of Cancer - EORTC" with 23 trials sponsored, "Centre Leon Berard" with 22 trials sponsored and "Nantes University Hospital" with 22 trials sponsored. Other sponsors include 667 different institutions and companies that sponsored additional 220 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU de Besançon" #1 collaborator was "Ministry of Health, France" with 22 trials as a collaborator, "National Cancer Institute, France" with 15 trials as a collaborator, "AstraZeneca" with 14 trials as a collaborator, "Hoffmann-La Roche" with 10 trials as a collaborator and "Merck Sharp & Dohme LLC" with 10 trials as a collaborator. Other collaborators include 729 different institutions and companies that were collaborators in the rest 473 trials.

According to Clinical.Site data, the most researched conditions in "CHU de Besançon" are "Breast Cancer" (34 trials), "Colorectal Cancer" (19 trials), "Multiple Myeloma" (13 trials), "Ovarian Cancer" (12 trials) and "Metastatic Colorectal Cancer" (11 trials). Many other conditions were trialed in "CHU de Besançon" in a lesser frequency.

Most popular intervention types in "CHU de Besançon" are "Drug" (482 trials), "Other" (214 trials), "Procedure" (112 trials), "Device" (100 trials) and "Biological" (70 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (66 trials), "Gemcitabine" (22 trials), "Paclitaxel" (22 trials), "fluorouracil" (16 trials) and "Bevacizumab" (15 trials). Other intervention names were less common.

The vast majority of trials in "CHU de Besançon" are 848 trials for "All" genders, 104 trials for "Female" genders and 36 trials for "Male" genders.

Currently, there are 362 active trials in "CHU de Besançon". 17 are not yet recruiting, 233 are recruiting, 108 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 429 completed trials in CHU de Besançon, 2 suspended trials, and 70 terminated clinical trials to date.

Out of the total trials that were conducted in CHU de Besançon, 28 "Phase 1" clinical trials were conducted, 209 "Phase 2" clinical trials and 265 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 41 trials, and there were also 222 trials that are defined as “Not Applicable".

CHU de Besançon has several departments that took part in Clinical trials: "HOPITAL JEAN MINJOZ; Oncologie" - 24 trials, "CHU Besancon - Pneumologie" - 19 trials, "CHU de Besancon Hopital Jean Minjoz; Service de Neurologie" - 6 trials, "Service de néphrologie, CHU de Besançon" - 5 trials, "CHU Besancon - Clinical Psychiatric Department" - 3 trials, "Service Hématologie, Hôpital Minjoz" - 2 trials